Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 15/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2432535 | 0.86 | ATR (0.42) | PLAUKDM6BKDM4CATRGRM5 | |
| Trifluoroacetic Acid SCHEMBL2430086 | 0.82 | HDAC6 (0.48) | PLAUATRGRM5 | |
| SCHEMBL12288578 | 0.80 | ATR (0.46) | PLAUKDM6BKDM4CATRGRM5 | |
| Trifluoroacetic Acid SCHEMBL2432623 | 0.79 | HDAC6 (0.51) | ATRGRM5 | |
| Trifluoroacetic Acid SCHEMBL2434092 | 0.78 | HDAC6 (0.50) | ATRGRM5 | |
| Trifluoroacetic Acid SCHEMBL2432097 | 0.78 | HDAC6 (0.49) | PLAUATRGRM5 | |
| SCHEMBL12288566 | 0.76 | HDAC6 (0.52) | PLAUATRGRM5 | |
| Trifluoroacetic Acid SCHEMBL2428006 | 0.76 | GRM5 (0.54) | PLAUATRGRM5 | |
| Trifluoroacetic Acid SCHEMBL2429159 | 0.75 | GRM5 (0.55) | PLAUATRGRM5 | |
| Trifluoroacetic Acid SCHEMBL2436371 | 0.74 | GRM5 (0.45) | ATRGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110217265-A1 | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217265-A1 | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function | NSF, HAVCR2, ABHD16A | PLAU 2458/4885TPSAB1 3740/4885KDM6B 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.